这是描述信息

天津全和诚科技有限责任公司,是一家成立于2010年10月的国家高新技术企业,总部位于天津市滨海新区,主要从事新药研发中间体和IVD原材料的CRO和CDMO的服务。公司由研发中心、中试平台和生产基地组成,分布在天津...

产品中心

PRODUCT CENTER

服务特色

医药中间体

天津全和诚科技有限责任公司,是一家成立于2010年10月的国家高新技术企业,总部位于天津市滨海新区

服务特色

PCR核心原料

天津全和诚科技有限责任公司,是一家成立于2010年10月的国家高新技术企业,总部位于天津市滨海新区

服务特色

核酸药物原料

天津全和诚科技有限责任公司,是一家成立于2010年10月的国家高新技术企业,总部位于天津市滨海新区

服务特色

荧光探针

天津全和诚科技有限责任公司,是一家成立于2010年10月的国家高新技术企业,总部位于天津市滨海新区

我们能为您提供哪些服务

What can we do for you?

分子砌块
imgboxbg

Molecular block

分子砌块

imgboxbg

The custom synthesis

定制合成

定制合成
工艺研发
imgboxbg

R&D

工艺研发

新闻中心

NEWS CENTER

12/02/2021

The COVID-19 detection concept is making a comeback! IVD may break out

Recently, COVID-19 mutant (Omicron) was discovered in southern Africa, and then spread rapidly in South Africa and around the world. The mutant has more mutations and faster transmission than delta virus, which has attracted much attention in the world. The vaccine giant Moderna CEO predicted that the existing vaccine would be far less effective than the early COVID-19 in dealing with it, and that large scale production of the new vaccine may take months. Under the background that the protective effect of vaccine may decline, it may be the most effective epidemic prevention method to isolate timely the source of infection through COVID-19 detection. Therefore, the support of COVID-19 detection reagent is indispensable for epidemic resistance at home and abroad. The implementation of home testing at home and abroad has also imperceptibly changed people's understanding and consumption concept of testing products. It indicates that in vitro diagnosis (IVD), especially Point-Of-CareTesting (POCT) in the subdivided field of IVD, will enter thousands of households gradually in the future. This has greatly promoted the trend of building an ecological closed loop of IVD and daily life health management in the industry. And this change will take place on a global field.   POCT is the future trend of IVD industry   What is POCT? What is the difference and relationship between it and IVD? There are many kinds of IVD products which are mainly used in hospitals. However, the traditional IVD products are not convenient and even can’t be used in many scenarios where medical personnel is absent, such as policeman checking drunk-driving, the home blood glucose test, and the health status detect of visitors at the customs. A new IVD equipment is required. It may not be able to meet the needs of the rapid detection of hundreds of products at one time by high-level equipment  in the high-speed inspection center. On the contrary, it will reached the other end: the equipment is very small and there are not many items that can be tested at one time. This is a popular product in the IVD industry recently, called POCT. Its full English name is Point-Of-CareTesting. POCT is a rapidly developing subdivision field in the world. According to the Global POCT Outlook report, the global market size in 2018 was about US $24 billion, with a compound growth rate of more than 8% from 2013 to 2018. Among them, except for the blood glucose monitoring market, which accounts for a large proportion of the POCT market, the growth rate of several other segments maintained a high growth rate of more than 10%. The world POCT market is mainly concentrated in the United States and Europe. It is expected that the size of the POCT market will exceed US $27 billion in 2020. The share of Asia Pacific POCT market in the global market is expected to continue to increase. According to BCC Research data, in 2018, the market scale of POCT in the Asia Pacific region was about US $5 billion, accounting for about 25% of the global market share; It is estimated that the Asia Pacific POCT market will exceed US $8 billion by 2023, accounting for 34% of the world.   At present, according to the statistics of relevant institutions, the penetration rate of IVD in China is significantly lower than that in developed countries. The penetration rate of POCT in developed countries such as Britain, America, Germany, France and Canada is generally about 30%, and it is still on the rise. In 2018, the penetration rate of POCT in the United States was about 30%, which is expected to grow steadily in the future and reach about 36% by 2023. According to Frost & Sullivan data, the penetration rate of China's POCT in 2018 was about 14.7%, lower than half of that of the United States. In the next five years, China's POCT market is expected to grow rapidly at the rate of 20% - 25%, and the penetration rate of China's POCT market to IVD will grow fastest in the world. In 2023, the penetration rate of POCT to IVD will increase most significantly, and will reach about 20% in 2023.   Source: Securities Star
View Article
The COVID-19 detection concept is making a comeback! IVD may break out
View Article

10/27/2021

Warmly congratulate our company on completing the round A financing of nearly 100 million yuan and building a domestic leading CDMO platform for small molecular drugs + IVD raw materials

On October 27, 2021, Official announcement issued by our company: Cosychem Technology (Tianjin) Co., Ltd. (Abbreviation: Cosychem) completed A round of financing of nearly 100 million yuan, led by Tianchuang capital, followed by Bozheng capital and Xinghan capital as the exclusive financial consultant. This round of financing will be mainly used for the construction of the company's production base and the R & D of new products, While consolidating the CDMO business of small molecule innovative drugs, it will further accelerate the production and transformation of core raw material business in the field of IVD. This financing is the first external financing of our company. In the development process of the first 10 years, Cosychem has completed the growth of output value from 0 to 100 million yuan by relying on its independent growth ability, and its business has gradually expanded from early CRO service to CDMO business. In the field of small molecule CDMO with relatively fierce competition, relying on years of experience in chemical synthesis and production amplification, our company has become the core supplier of many leading pharmaceutical enterprises. In 2013, our company began to layout IVD raw materials and successfully developed several key IVD raw material products such as dNTP and fluorescent probe. Our company will also further deepen the construction of R & D platform with the support of this financing. "In the past, the company focused on technology R & D services, and most of the orders were customized products with high added value but less volume. In the future, the company will focus on large-scale production of key technical achievements, create products with market leading position, provide one-stop services from R & D to production, and establish the Cosychem brand to realize early intervention and deep binding of the innovative pharmaceutical projects We will keep the key core technologies in our own hands and make continuous efforts for the rapid and stable development of biomedicine." Mr Yanmin Song, founder of the company, said.  
View Article
Warmly congratulate our company on completing the round A financing of nearly 100 million yuan and building a domestic leading CDMO platform for small molecular drugs + IVD raw materials
View Article
这是描述信息

热线电话: 022-65378456

地址:天津经济技术开发区第四大街80号天大科技园

关注我们

公众号二维码

官方公众号

Copyright © 2021 天津全和诚科技有限责任公司    网站建设:中企动力  天津   津ICP备**********号